KevinMD August 10, 2024
According to some academics, in 2019, a ban on junk food advertising across London’s entire public transport network—foods and drinks high in fat and salt and ads for foods–resulted in the prevention of 100,000 obesity cases. Yet the U.S. love affair with the new semaglutide-based weight loss drugs like Ozempic gives junk food advertising and availability a huge pass.
Drug makers and Wall Street are pleased that instead of changing their eating habits, fat people are rushing toward drugs that can be listed at $935.77 per single dose (compute that annually!), raising everyone’s health care costs and taxes from entitlement programs like Medicare. People who don’t overeat are carrying the cost weight, pun intended, along with fat people.
Like Vioxx,...
Today's Sponsors
Today's Sponsor